Skip to main content

Select Drug Profiles

FDA Approvals, Select Drug Profiles

Lumakras First FDA-Approved Therapy for Advanced or Metastatic NSCLC with KRAS G12C Mutation

FDA Approvals, Select Drug Profiles

Zynlonta First FDA-Approved CD19-Directed Therapy for Large B-Cell Lymphoma

FDA Approvals, Select Drug Profiles

Cosela First CDK4/6 Inhibitor FDA Approved to Reduce Chemotherapy-Induced Myelosuppression

FDA Approvals, Select Drug Profiles

Vyxeos Now Indicated for Treatment of Pediatric Patients with AML

FDA Approvals, Lymphoma, Select Drug Profiles

FDA Approved Ukoniq, New Targeted Therapy, for Marginal-Zone and Follicular Lymphoma

FDA Approvals, Lymphoma, Select Drug Profiles

FDA Approved Breyanzi, Novel CAR T-Cell Therapy, for Large B-Cell Lymphoma

FDA Approvals, Multiple Myeloma, Select Drug Profiles

FDA Approved Pepaxto for Relapsed or Refractory Multiple Myeloma

FDA Approvals, Multiple Myeloma, Select Drug Profiles

FDA Approved Abecma, First CAR T-Cell Therapy for Multiple Myeloma

FDA Approvals, Select Drug Profiles

Keytruda plus Chemotherapy Approved for Unresectable or Metastatic Triple‑Negative Breast Cancer

FDA Approvals, Select Drug Profiles

Opdivo plus Yervoy First Immunotherapy Approved for Unresectable Malignant Pleural Mesothelioma

1
2
3
4
5

Page 2 of 20
Results 11 - 20 of 200